Showing results (51-60 of 74) with videos related to
Sort By:
Pageof 8
The British Journal of Dermatology|April 20, 2022
The Validated Investigator Global Assessment for Atopic Dermatitis (vIGA-AD™): a clinical outcome measure for the severity of atopic dermatitisEric L Simpson, Robert Bissonnette, Amy S Paller, et al.Journal of the American Academy of Dermatology|March 24, 2021
A phase 2a randomized, placebo-controlled study to evaluate the efficacy and safety of the oral Janus kinase inhibitors ritlecitinib and brepocitinib in alopecia areata: 24-week resultsBrett King, Emma Guttman-Yassky, Elena Peeva, et al.Journal of the American Academy of Dermatology|July 25, 2024
Efficacy and safety of deuruxolitinib, an oral selective Janus kinase inhibitor, in adults with alopecia areata: Results from the Phase 3 randomized, controlled trial (THRIVE-AA1)Brett King, Maryanne M Senna, Natasha A Mesinkovska, et al.The British Journal of Dermatology|February 10, 2023
Integrated safety analysis of baricitinib in adults with severe alopecia areata from two randomized clinical trialsBrett King, Arash Mostaghimi, Yutaka Shimomura, et al.The British Journal of Dermatology|March 29, 2026
Deucravacitinib, an oral, selective, allosteric tyrosine kinase 2 inhibitor, in patients with alopecia areata: efficacy and safety results of a phase II, multicenter, randomized, double-blinded, placebo-controlled trialBrett King, Benjamin Ehst, Peter Foley, et al.American Journal of Clinical Dermatology|January 23, 2024
Integrated Safety Analysis of Ritlecitinib, an Oral JAK3/TEC Family Kinase Inhibitor, for the Treatment of Alopecia Areata from the ALLEGRO Clinical Trial ProgramBrett King, Jennifer Soung, Christos Tziotzios, et al.Experimental Dermatology|September 20, 2024
Efficacy and safety of ritlecitinib in vitiligo patients across Fitzpatrick skin types with biomarker analysesElena Peeva, Yuji Yamaguchi, Zhan Ye, et al.The New England Journal of Medicine|March 25, 2022
Two Phase 3 Trials of Baricitinib for Alopecia AreataBrett King, Manabu Ohyama, Ohsang Kwon, et al.Journal of the American Academy of Dermatology|October 18, 2024
Sustained hair regrowth with continued ritlecitinib treatment through week 48 in patients with alopecia areata with or without early target responses: Post hoc analysis of the ALLEGRO phase 2b/3 trialMelissa Piliang, Charles Lynde, Brett King, et al.Immunotherapy|July 5, 2023
A plain language summary on ritlecitinib treatment for adults and adolescents with alopecia areataBrett King, Xingqi Zhang, Walter Gubelin Harcha, et al.Pageof 8